L

Lixte Biotechnology Holdings

D
LIXT
USD
-0.175
(-9.7493%)
Market Closed
1,650.00
Volume
EPS
-
Div Yield
-0.941860
P/E
3,643,849.80
Market Cap
Today
-9.7493%
1 Week
-23.944%
1 Month
-10.989%
6 Months
-44.138%
12 Months
-48.243%
Year To Date
-31.064%
All Time
-95.703%

Title:
Lixte Biotechnology Holdings

Sector:
Healthcare
Industry:
Biotechnology
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. Itfocuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Do you need help or have a question?